• Why FIH Budgets Are Hard to Estimate Early
• The Major Cost Drivers in a Medical Device FIH Study
  • 1. Regulatory Strategy and Pre-Submission Work
  • 2. Ethics and Regulatory Approval Timelines
  • 3. Site Activation and Investigator Fees
  • 4. Patient Enrollment
  • 5. Data Management and EDC
  • 6. Safety Monitoring and Adverse Event Reporting
  • 7. Clinical Study Report and Submission Package
• How Program Structure Affects Total Cost
• Geography as a Budget Variable
• Common Budget Mistakes to Avoid
• Building a Budget That Fits Your Capital Cycle
• FAQs

Planning a clinical trial budget is one of the most consequential decisions a medical device startup makes before first-in-human work begins. Get it right, and you protect your runway while hitting the data milestone your next funding round depends on. Get it wrong, and you either burn cash on delays or arrive at your Series B with incomplete evidence.

This article breaks down the real cost drivers in a first-in-human (FIH) medical device study — where budgets tend to slip, and how geography and program structure affect what you actually spend.

---

Why FIH Budgets Are Hard to Estimate Early

Most founders underestimate FIH costs because they anchor on a single line item — usually the CRO fee — and treat everything else as rounding error. In practice, that fee is only one component of a budget that spans regulatory strategy, site operations, patient enrollment, data management, and submission preparation.

The other common mistake is treating a US-based CRO quote as the only benchmark. US and EU trial infrastructure carries a cost structure built for large pharma programs. When a startup with $2 million allocated for FIH work receives a quote sized for a 24-month, multi-site Phase I at a US academic medical center, the numbers rarely fit.

---

The Major Cost Drivers in a Medical Device FIH Study

1. Regulatory Strategy and Pre-Submission Work

Before a single patient is enrolled, you need a clear FDA pathway and a protocol that will generate data FDA will accept. That means Pre-Sub meetings, IDE preparation where applicable, and protocol architecture aligned to your 510(k), De Novo, PMA, or HDE route.

This workstream is consistently underbudgeted because it feels like planning rather than execution. But a protocol that misaligns with your intended regulatory pathway can force an amendment mid-study — and amendments cost both time and money. Solid regulatory strategy work at the front end is one of the most cost-efficient investments in the entire budget.

2. Ethics and Regulatory Approval Timelines

Approval timelines directly affect burn rate. Every month your study sits in a regulatory queue is a month of overhead, staff time, and deferred data.

In the US and EU, ethics and regulatory approvals typically take 6 to 12 months. In Panama, El Salvador, Chile, and the Dominican Republic, the same approvals are observed in 30 to 90 days. That difference alone can represent several hundred thousand dollars in carrying costs for a startup maintaining a standing team, device inventory, and site readiness while waiting.

Geography is a budget variable, not just a logistics preference.

3. Site Activation and Investigator Fees

Site activation covers site qualification, contract negotiation, ethics submissions at the site level, and investigator training. For a multi-site study, these costs multiply quickly.

Investigator fees vary significantly by country and specialty. Device trials requiring surgical implantation or specialized procedural skills command higher per-procedure fees than simpler interventional studies. Budgeting accurately here requires knowing your device category, the investigator profile the protocol demands, and the site's patient volume in your target indication.

Working with a network of pre-qualified sites reduces activation time and can lower the cost of feasibility work. A CRO with established site relationships doesn't need to rebuild that infrastructure from scratch for each new sponsor.

4. Patient Enrollment

Enrollment is where most FIH budgets experience their largest unplanned overruns. The primary causes are overly optimistic enrollment rate assumptions and underestimated screen failure rates.

Eligibility criteria in medical device FIH studies tend to be narrow. You may need a specific anatomical profile, disease severity range, or prior treatment history. Screen failure rates of 30 to 50 percent are common. If your budget assumes a one-to-one screening-to-enrollment ratio, you will run out of money before you hit your sample size.

Enrollment costs include patient stipends, screening visits, protocol-required diagnostics, and site staff time per patient contact. In jurisdictions with strong patient availability for your indication and experienced site coordinators, these costs are lower and enrollment moves faster.

5. Data Management and EDC

Electronic data capture setup, data entry, query resolution, and database lock are both fixed and variable costs that scale with protocol complexity and visit count. A lean protocol with fewer endpoints and fewer visits costs less to manage than a heavily instrumented study.

This is worth considering at the protocol design stage. Every additional data collection point adds cost downstream. Protocol authors who haven't managed data operations often add endpoints that sound useful but are expensive to collect and never appear in the final submission package.

6. Safety Monitoring and Adverse Event Reporting

For a first-in-human study, safety monitoring is non-negotiable. This includes a Data Safety Monitoring Board or equivalent independent review, Medical Monitor fees, and the infrastructure to capture, adjudicate, and report adverse events in compliance with ICH-GCP and ISO 14155 standards.

Adverse event reporting workflows that are well-structured from the outset cost less to operate than those assembled after enrollment begins.

7. Clinical Study Report and Submission Package

The end product of a FIH study is not raw data. It is a clinical study report and an organized data room structured for your next FDA regulatory step. Under FDA 21 CFR 812.28, foreign clinical data collected under the appropriate framework is accepted for US IDE and IND submissions — but the data must be organized and presented in a format FDA can use.

Sponsors who treat the CSR as an afterthought often face significant cost and time reconstructing documentation that should have been captured prospectively. Building the submission package into the program from day one keeps this cost predictable.

---

How Program Structure Affects Total Cost

The difference between a structured FIH program and a fragmented vendor approach is meaningful from a budget standpoint.

When a sponsor coordinates regulatory consultants, a CRO, a site management organization, a data management vendor, and a medical writer as separate contracts, they pay for the overhead of managing all those relationships. Each vendor has its own scope boundaries, change order process, and communication overhead. Gaps between vendor scopes become the sponsor's problem to resolve — and resolving them costs money.

A single-vendor program covering all workstreams under one engagement eliminates that coordination tax. It also makes the budget more predictable because scope is defined once, not renegotiated across five separate contracts.

bioaccess® structures its FIH-12™ program around nine workstreams managed by one accountable team — from FDA strategy alignment and protocol development through site activation, enrollment, data management, and final submission-ready evidence package delivery. The 12-month timeline is designed to fit within a startup's capital cycle between funding rounds.

---

Geography as a Budget Variable

Running a FIH study in the US or EU is not inherently more rigorous than running one in a jurisdiction with faster approvals. What matters is whether the data is collected under a framework FDA will accept and whether the protocol architecture meets the applicable standard.

Under FDA 21 CFR 812.28, clinical data collected outside the US is accepted for US regulatory submissions when the study meets applicable requirements. Protocols built to ISO 14155 architecture, with ACRP-certified clinical operations, produce data that travels to FDA submissions.

The budget implication is direct. A 30 to 90-day approval window in Panama, El Salvador, Chile, or the Dominican Republic versus a 6 to 12-month window in the US means a faster enrollment start, lower carrying costs, and a submission-ready dataset delivered within a timeline that aligns with your next funding milestone.

---

Common Budget Mistakes to Avoid

Anchoring on a single line item. The CRO fee is visible; site costs, regulatory delays, and screen failure overruns are not. Budget for the full program, not just the contract.

Underestimating screen failures. Build a realistic screen failure assumption into your enrollment budget from the start. For most device FIH studies, plan for at least a 2:1 screening-to-enrollment ratio.

Treating submission preparation as separate. The CSR and data room are part of the study, not a separate project. If your budget doesn't include them, your total cost estimate is incomplete.

Ignoring approval timeline costs. A 9-month regulatory queue is not free. It carries a real cost in staff time, site readiness, and deferred data. Factor approval timelines into your total program cost, not just your CRO fee.

Choosing a CRO by lowest fee. A low CRO fee attached to a 24-month timeline and fragmented workstreams may cost more in total than a higher fee attached to a 12-month structured program with single-vendor accountability.

---

Building a Budget That Fits Your Capital Cycle

For seed-to-Series-B medical device startups, the FIH budget is not purely a clinical operations question — it is a capital strategy question. The goal is a submission-ready dataset before your next funding round closes, delivered within the $1 million to $5 million range most early-stage programs are working with.

That requires a program structure where timeline, scope, and cost are defined together, not independently. It requires a geography where approvals don't consume half your runway. And it requires a CRO that can deliver the full evidence package, not just enrollment.

The early-phase CRO services market reached USD 6.73 billion in 2026 per Mordor Intelligence, reflecting how central this decision has become for life sciences startups. Choosing the right program structure and jurisdiction is one of the highest-leverage decisions in that market.

If you are at the stage of building your FIH budget, the bioaccess® FIH Launch Planner generates a preliminary country route, timeline range, and evidence package estimate from six sponsor inputs — a practical starting point before you issue an RFP.

---

FAQs

What is a realistic budget range for a medical device FIH study?
Most medical device FIH studies at seed-to-Series-B startups fall in the $1 million to $5 million range, depending on device complexity, sample size, number of sites, and the jurisdiction where the study runs. This range covers regulatory strategy, site activation, enrollment, data management, and submission preparation.

Does running a FIH study in Latin America cost less than running one in the US?
Geography affects both direct costs and timeline costs. In Panama, El Salvador, Chile, and the Dominican Republic, regulatory approvals take 30 to 90 days versus 6 to 12 months in the US or EU. Faster approvals reduce carrying costs and get you to enrollment sooner, which affects total program cost in a meaningful way.

Will FDA accept data from a FIH study conducted in Latin America?
Under FDA 21 CFR 812.28, clinical data collected outside the US is accepted for US IDE and IND submissions when the study meets applicable requirements. Protocols built to ISO 14155 architecture and conducted under ICH-GCP standards produce data that supports US regulatory submissions. FDA acceptance of foreign clinical data under this framework is not unconditional approval of the trial itself, but the pathway is well-established.

What causes FIH clinical trial budgets to overrun?
The most common causes are underestimated screen failure rates, regulatory approval delays that extend carrying costs, scope gaps between fragmented vendors, and treating submission preparation as a separate project rather than part of the study budget.

How does a single-vendor CRO program affect budget predictability?
When one team manages all workstreams under a single engagement, scope is defined once and change orders are less frequent. Fragmented vendor models require sponsors to manage scope boundaries across multiple contracts, which creates cost exposure that is difficult to budget in advance.

What is the minimum sample size for a medical device FIH study?
There is no universal minimum. Sample size depends on your regulatory pathway, the endpoints you need to support, and the statistical requirements of your protocol. IDE feasibility studies often enroll 10 to 30 subjects, while studies supporting a 510(k) or De Novo may require larger cohorts. Your protocol architecture and FDA pathway determine the number.

When should a startup start planning its FIH budget?
Ideally 12 to 24 months before you need first human data. That window allows time for regulatory strategy alignment, protocol development, site selection, and approval processes without compressing your timeline. Starting budget planning after IDE approval or a Series A close is common, but it leaves less margin for adjustment.

---

Planning your clinical trial budget well before you need it is not excessive caution — it is how startups protect their runway and arrive at their next funding milestone with the data they promised. The decisions you make on program structure, geography, and vendor accountability shape not just what you spend, but whether you spend it on time.

• What PMA Means
• Which Devices Require PMA
• The PMA Application: What It Actually Contains
• The Role of First-in-Human Data in a PMA Program
• Why Sponsors Running PMA-Track Devices Look Beyond the US for FIH Studies
• PMA vs. Other FDA Pathways: A Practical Comparison
• What Makes a PMA Clinical Program Succeed
• Planning Your PMA Timeline as a Startup
• FAQs

If you're developing a high-risk medical device and someone tells you it needs a PMA, that's not a minor regulatory detail. It means your path to US market clearance will require the most demanding clinical evidence package the FDA asks for. Understanding what PMA means, when it applies, and what it actually demands from a clinical program is foundational for any MedTech founder planning their development timeline and capital strategy.

What PMA Means

PMA stands for Premarket Approval. It's the FDA's regulatory mechanism for Class III medical devices — those that sustain or support human life, are implanted in the body, or present a potential unreasonable risk of illness or injury.

Unlike the 510(k) pathway, which clears a device based on substantial equivalence to a predicate, PMA requires the sponsor to independently demonstrate that the device is safe and effective. The FDA isn't comparing your device to something already on the market. It's evaluating the scientific evidence you generate entirely on its own merits.

That distinction has significant consequences for clinical planning. A 510(k) submission can sometimes rely on bench testing and limited clinical data. A PMA application typically requires a full pivotal clinical trial with statistically powered endpoints — often preceded by first-in-human feasibility data to support the pivotal design.

Which Devices Require PMA

Class III is the operative classification. Devices automatically placed in Class III include those that are life-sustaining, life-supporting, or implanted, and for which there's insufficient information to determine that general controls and performance standards would provide reasonable assurance of safety and effectiveness.

Common examples include:

• Implantable cardiac defibrillators
• Left ventricular assist devices
• Cochlear implants
• Certain neurostimulation systems
• High-risk ophthalmic implants
• Novel vascular grafts without a predicate

A device can also be required to go through PMA if it was originally classified as Class III at the time of the Medical Device Amendments of 1976, or if a De Novo classification request is denied and the device remains Class III.

If you're unsure of your device's classification, the FDA's product code database and a Pre-Submission (Pre-Sub) meeting are the right starting points. Misclassifying your device early creates downstream risk that compounds as your program advances.

The PMA Application: What It Actually Contains

A complete PMA submission is a substantial document. The FDA reviews it against a defined set of required elements, and any deficiency can trigger a Major Deficiency letter that resets the review clock.

The core components include:

Device description and manufacturing information. Full technical documentation covering design specifications, materials, manufacturing processes, and quality system compliance.

Non-clinical laboratory studies. Bench testing, biocompatibility data, electrical safety, software validation, and animal study results. These preclinical studies establish the safety foundation before any human exposure.

Clinical investigation data. This is the weight-bearing component of most PMA applications. The FDA expects data from well-controlled clinical studies demonstrating that the device performs as intended in the target patient population. The clinical data section must include the study protocol, IRB approvals, patient demographics, primary and secondary endpoint results, adverse event reporting, and a complete clinical study report.

Risk-benefit analysis. A structured analysis showing that the probable benefits of the device outweigh its probable risks for the intended use population.

Proposed labeling. Draft instructions for use, indications, contraindications, warnings, and precautions.

References. Published literature supporting the scientific rationale and clinical context.

The FDA has 180 days to review a PMA application once it's accepted as complete — though the actual timeline from submission to approval is typically longer when you account for deficiency responses and panel meetings.

The Role of First-in-Human Data in a PMA Program

Most PMA-track devices don't go straight from animal studies to a pivotal trial. The standard development arc includes an early feasibility or first-in-human (FIH) study that generates initial safety and performance data in a small patient cohort, followed by a pivotal trial designed with the statistical power to support the PMA application.

The FIH study serves several functions. It confirms the device can be safely used in humans at all. It surfaces any unexpected adverse events that need to be addressed before scaling enrollment. It generates preliminary effectiveness signals that inform pivotal endpoint selection. And it produces the clinical evidence needed to support an IDE application for the pivotal trial — or to refine an existing one.

For startups on a Series A or Series B timeline, the FIH study is often the most capital-efficient milestone to hit before the next funding round. Investors want to see human data. A FIH dataset is what moves a device from "promising preclinical results" to "de-risked asset with clinical proof of concept."

The challenge is that running a FIH study in the US takes time. Ethics and regulatory approvals typically require 6–12 months before the first patient is enrolled. For a founder with 18 months of runway and a board milestone tied to a pivotal trial start, that timeline is a serious constraint.

Why Sponsors Running PMA-Track Devices Look Beyond the US for FIH Studies

FDA regulations under 21 CFR 812.28 explicitly permit the use of foreign clinical data in IDE and PMA submissions, provided the data was collected under conditions comparable to FDA standards and the studies were conducted in accordance with Good Clinical Practice.

This isn't a workaround. It's a documented regulatory framework that allows PMA-track sponsors to generate FIH data in jurisdictions with faster approval timelines, then use that data to support their US regulatory submissions.

Latin America has become a recognized jurisdiction for this purpose. Panama, El Salvador, Chile, and the Dominican Republic have ethics and regulatory review processes that operate on 30–90-day timelines — compared to the 6–12 months typical in the US or EU. That difference can compress a FIH program by six months or more, which is material when your next funding round has a defined close date.

bioaccess® manages FIH clinical trials specifically for MedTech and Biopharma startups across these four jurisdictions. Its FIH-12™ program is a structured 9-workstream engagement designed to take a sponsor from protocol development to a submission-ready clinical evidence package within 12 months. Every study is aligned to the sponsor's intended US regulatory pathway from day one — PMA, IDE, 510(k), De Novo, or HDE — so the final data package is built for the sponsor's next FDA step.

PMA vs. Other FDA Pathways: A Practical Comparison

Understanding where PMA sits relative to other pathways helps clarify when it applies and when an alternative might be available.

Pathway	Device Class	Clinical Evidence Required	Typical Timeline
510(k)	Class II (mostly)	Substantial equivalence to predicate; clinical data often limited	3–12 months
De Novo	Class II (novel)	Performance data; clinical data may be required	12–24 months
PMA	Class III	Independent clinical trial demonstrating safety and effectiveness	3–7+ years total program
HDE	Class III (rare disease)	Probable benefit; less rigorous than full PMA	Similar to PMA but with lower evidence threshold

The Humanitarian Device Exemption (HDE) is worth noting for sponsors developing devices for conditions affecting fewer than 8,000 patients per year in the US. The evidence threshold is lower than a full PMA, but the pathway is only available for qualifying rare disease indications.

If your device is Class III but has a predicate cleared before the 1976 amendments, a 510(k) may still be available. That's a nuanced determination that requires Pre-Sub engagement with the FDA.

What Makes a PMA Clinical Program Succeed

The FDA's standard for PMA approval is "reasonable assurance of safety and effectiveness." That phrase sounds straightforward, but translating it into a clinical program that actually meets the standard requires several things to be true at once.

Endpoint selection must be clinically meaningful and measurable. The FDA won't approve a device based on surrogate endpoints alone if direct clinical benefit endpoints are feasible. Choosing endpoints that are both scientifically valid and practically achievable in your patient population is one of the most consequential decisions in PMA program design.

The study population must reflect the intended use population. Enrollment criteria that are too narrow produce data the FDA may not accept as generalizable. Criteria that are too broad create heterogeneity that obscures the safety and effectiveness signal.

Adverse event reporting must be complete and transparent. PMA reviewers scrutinize adverse event data closely. Incomplete or inconsistently reported events are a common source of Major Deficiency letters.

The clinical study report must be organized for FDA review. A PMA application isn't just a collection of data — it's a structured argument that the evidence supports approval. The clinical study report and supporting data room need to be organized in a way that makes the FDA reviewer's job tractable.

For startups, this last point is frequently underestimated. A well-organized, submission-ready evidence package can meaningfully accelerate FDA review. A disorganized one adds months to the process.

Planning Your PMA Timeline as a Startup

A full PMA program from FIH study to approval typically spans several years. That doesn't mean every phase needs to move at the same pace. The FIH and early feasibility phases are where startups have the most flexibility to compress timelines, because the regulatory approval bottleneck is shorter and enrollment numbers are smaller.

A realistic planning framework for a PMA-track device looks something like this:

1. Pre-clinical completion and design freeze. Bench testing, biocompatibility, and animal studies complete. Design locked.
2. Pre-Sub meeting with FDA. Confirm classification, discuss IDE requirements, and align on the clinical evidence needed for PMA.
3. FIH / early feasibility study. Small cohort — typically 5–30 patients — to establish initial safety and performance data. This is where Latin American jurisdictions with 30–90-day approval timelines offer a meaningful speed advantage.
4. IDE application for pivotal trial. FIH data supports the IDE. FDA review takes approximately 30 days for non-significant risk determinations, or up to 30 days after receipt for significant risk devices.
5. Pivotal clinical trial. Statistically powered enrollment. This is the weight-bearing clinical phase for the PMA application.
6. PMA submission and review. 180-day statutory review period, plus time for deficiency responses.

Founders who treat the FIH study as a capital-efficient milestone — rather than a regulatory formality — tend to enter the pivotal phase with better data, a more refined protocol, and a stronger investor narrative.

---

FAQs

What does PMA stand for in medical devices?
PMA stands for Premarket Approval. It's the FDA's most rigorous review process for Class III medical devices, requiring the sponsor to independently demonstrate that the device is safe and effective through clinical evidence — not by showing equivalence to a predicate device.

What is the difference between a 510(k) and a PMA?
A 510(k) clears a device based on substantial equivalence to a legally marketed predicate. A PMA requires the sponsor to generate original clinical evidence demonstrating safety and effectiveness. PMA applies to Class III devices; 510(k) applies primarily to Class II. The evidentiary burden and timeline for PMA are substantially higher.

Does a PMA application require a clinical trial?
In most cases, yes. PMA applications for novel Class III devices typically require data from at least one well-controlled clinical investigation. For many devices, the program includes an early feasibility or first-in-human study followed by a pivotal trial with statistically powered enrollment.

Can foreign clinical data be used in a PMA submission?
Yes. Under FDA 21 CFR 812.28, foreign clinical data may support a PMA application if it was collected under conditions comparable to FDA standards and the study was conducted in accordance with Good Clinical Practice. This is a documented regulatory framework, not an exception.

How long does PMA approval take?
The FDA has a 180-day statutory review period once a PMA application is accepted as complete. The total time from initial FIH study to PMA approval — including all clinical phases — typically spans several years, depending on device complexity, enrollment timelines, and the number of deficiency cycles during review.

What is a Humanitarian Device Exemption (HDE) and how does it differ from PMA?
An HDE is a pathway for Class III devices intended to treat or diagnose conditions affecting fewer than 8,000 patients per year in the US. The evidentiary standard is "probable benefit" rather than the full "reasonable assurance of safety and effectiveness" required for PMA. HDE-approved devices may not be sold for profit unless certain conditions are met.

When should a MedTech startup engage a CRO for a PMA-track device?
Before the FIH study — ideally during or immediately after the Pre-Sub meeting with FDA. Early engagement ensures the FIH protocol is designed to generate data that directly supports the IDE application and, ultimately, the PMA submission. Engaging a CRO after the FIH study is complete often means the data package needs to be restructured, which adds time and cost.

---

The meaning of PMA is straightforward on its face: it's the FDA's highest-evidence approval pathway for devices with the most direct impact on patient safety. What it means for your development program is more specific. Your clinical evidence package needs to be built from the ground up, and every study you run — starting with the first human exposure — needs to be structured to support that submission.

If you're planning a PMA-track program and want to understand how your FIH study fits into the broader regulatory strategy, bioaccess® works exclusively with MedTech and Biopharma startups on first-in-human programs aligned to FDA pathways including PMA, IDE, and De Novo.